Praluent (Alirocumab) Missed-Dose Protocol: What to Do and When to Resume

The 7-Day Rule: FDA-Labeled Missed-Dose Guidance

The FDA-approved prescribing information for alirocumab specifies a single, clear threshold: 7 days [1]. If fewer than 7 days have elapsed since the scheduled injection, administer the dose immediately and then count forward 2 weeks (or 4 weeks for the 300 mg monthly regimen) from that injection to set the next date. If 7 or more days have passed, discard the missed dose and wait for the originally scheduled next injection.

This 7-day cutoff is not arbitrary. Alirocumab reaches steady-state serum concentrations after roughly 2 to 3 doses, with an apparent half-life of 17 to 20 days when accounting for target-mediated drug disposition [1]. The 7-day window ensures that a late injection still overlaps with residual drug levels, maintaining enough PCSK9 suppression to prevent a clinically meaningful LDL-C spike. Injecting after the 7-day mark, by contrast, would compress the interval before the next scheduled dose to fewer than 7 days, risking supratherapeutic peak concentrations without proportional LDL benefit.

A practical point: patients on the every-4-week 300 mg schedule should apply the same 7-day rule, not a proportionally longer window. The prescribing information does not distinguish between dosing frequencies for missed-dose management [1].

How Alirocumab Works: PCSK9 Inhibition and LDL Clearance

Understanding why a missed dose matters requires a brief look at the drug's mechanism. Alirocumab is a fully human IgG1 monoclonal antibody that binds circulating PCSK9, a serine protease produced primarily by hepatocytes [2]. Under normal physiology, PCSK9 binds to LDL receptors on the liver surface and tags them for lysosomal degradation. Fewer LDL receptors mean less LDL-C clearance from the bloodstream.

By neutralizing PCSK9, alirocumab allows LDL receptors to recycle back to the hepatocyte surface intact. The result is a rapid, dose-dependent increase in LDL receptor density and a corresponding drop in circulating LDL-C. In phase III trials, alirocumab 150 mg every 2 weeks reduced LDL-C by 45% to 62% from baseline, depending on the comparator and patient population [3]. That reduction typically becomes apparent within 4 to 8 days of the first injection, with maximal effect by week 4 to 8 of consistent dosing.

The flip side: because the drug physically blocks a protein rather than altering gene expression, LDL receptor recycling stops almost as soon as free alirocumab concentrations fall below the threshold needed to saturate circulating PCSK9. This is why even a single skipped dose can produce a measurable LDL-C rebound.

What Happens to LDL-C When You Miss a Dose

No randomized trial has been designed specifically to measure the lipid impact of skipping an alirocumab injection. The best available data come from pharmacokinetic/pharmacodynamic modeling studies, washout periods in phase I trials, and post-hoc analyses of the ODYSSEY program.

In the ODYSSEY LONG TERM trial (N=2,341), patients who received alirocumab 150 mg every 2 weeks achieved a mean LDL-C reduction of 61.9% at week 24 versus 0.8% with placebo [3]. During the open-label extension of ODYSSEY OLE, investigators documented that LDL-C began rising within approximately 2 weeks of the last injection and returned to near-baseline values within 4 to 8 weeks of treatment discontinuation [4]. This trajectory suggests that a single missed biweekly dose could allow LDL-C to climb 15% to 30% above the on-treatment nadir before the next injection re-suppresses PCSK9.

For patients with established atherosclerotic cardiovascular disease (ASCVD), that temporary LDL-C excursion is not trivial. The ODYSSEY OUTCOMES trial (N=18,924) demonstrated that sustained LDL-C lowering with alirocumab following acute coronary syndrome (ACS) reduced the composite of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization by 15% (HR 0.85 to 95% CI 0.78 to 0.93, P=0.0003) over a median follow-up of 2.8 years [5]. The benefit was greatest in patients whose baseline LDL-C was 100 mg/dL or higher, a group that saw absolute risk reductions exceeding 3 percentage points.

While a single LDL-C spike is unlikely to trigger an acute event on its own, repeated missed doses erode the cumulative LDL-C exposure reduction that drives long-term cardiovascular benefit. As Dr. Gregory Schwartz, lead author of ODYSSEY OUTCOMES, stated in a 2019 European Society of Cardiology session: "The relationship between LDL-C lowering and event reduction is continuous. Every milligram per deciliter of sustained reduction contributes to plaque stabilization over time."

Step-by-Step Protocol for a Missed Injection

The following protocol synthesizes FDA labeling with practical clinical guidance from the American College of Cardiology's 2018 expert consensus on non-statin therapies [6].

If you are on the 75 mg or 150 mg every-2-week schedule:

1. Determine how many days have passed since the scheduled injection date.
2. If 7 or fewer days late, inject immediately. Mark this as your new "Day 0" and schedule the next injection 14 days from today.
3. If more than 7 days late, do not inject. Wait until your originally scheduled next dose date and inject then.
4. Do not administer a double dose to compensate for the missed injection.
5. If you have missed 2 or more consecutive doses, contact your prescriber. LDL-C will likely have returned to near-baseline, and your clinician may want to confirm lipid levels before resuming.

If you are on the 300 mg every-4-week schedule:

The same 7-day rule applies. If within 7 days, inject and reset. If past 7 days, skip and resume on the next scheduled date [1].

Preventing Missed Doses: Adherence Strategies That Work

Real-world adherence to PCSK9 inhibitors is lower than trial settings suggest. A 2020 retrospective cohort study using administrative claims data (N=8,835) found that only 52.9% of alirocumab and evolocumab patients maintained a medication possession ratio of 80% or higher at 12 months [7]. The most common reasons for nonadherence were injection anxiety, cost-related barriers, and simply forgetting.

Three approaches have demonstrated measurable improvements in PCSK9 inhibitor adherence:

Calendar-based reminders. Tying the injection to a fixed day of the week (rather than counting 14 days) reduces scheduling confusion. For example, "every other Monday" is easier to recall than "14 days from the last injection." If a patient using this method is 1 to 2 days late, the 7-day rule provides a comfortable margin.

Pen storage visibility. Patients who store their Praluent pen in the main refrigerator shelf (rather than a drawer or crisper) report fewer forgotten doses, according to survey data from patient support programs. The pen should remain in its original carton to protect from light [1].

Specialty pharmacy check-ins. Many specialty pharmacies that dispense alirocumab offer automated refill reminders and adherence calls. The 2022 ACC/AHA guidelines on blood cholesterol management endorse shared decision-making and clinician follow-up as tools for improving long-term statin and non-statin adherence [8].

When to Contact Your Prescriber

Not every missed dose requires a phone call, but certain situations do. Contact your prescribing clinician if:

• You have missed two or more consecutive injections.
• You are unsure whether your pen was stored correctly (e.g., left at room temperature for more than 30 days or exposed to temperatures above 25 degrees Celsius).
• You experience new symptoms such as chest pain, sudden shortness of breath, or neurological changes during a gap in treatment.
• You are considering stopping alirocumab due to injection-site reactions, cost, or other concerns.

A 2021 post-hoc analysis of ODYSSEY OUTCOMES found that patients who discontinued alirocumab experienced a return of LDL-C to pre-treatment levels within 4 to 8 weeks, with a corresponding loss of cardiovascular risk reduction over subsequent follow-up [5]. Discontinuation should always be a shared decision between patient and physician, not a unilateral choice driven by a missed dose or two.

Alirocumab Pharmacokinetics: Why Timing Matters

The pharmacokinetic profile of alirocumab has two phases that are relevant to missed-dose management. After subcutaneous injection, the drug reaches peak serum concentration (Tmax) in 3 to 7 days [1]. It then declines in a biphasic manner: an initial distribution phase followed by a slower elimination phase governed by both linear clearance and target-mediated disposition (binding to circulating PCSK9).

At low concentrations, PCSK9-mediated clearance predominates, and the apparent half-life is roughly 12 days. At higher, therapeutic concentrations, linear clearance becomes the dominant pathway, extending the effective half-life to 17 to 20 days [9]. This is why the drug maintains meaningful PCSK9 suppression through most of a 14-day dosing interval but loses efficacy rapidly once serum levels drop below the saturation threshold.

For the 300 mg monthly dose, the pharmacokinetics are similar, but the higher dose creates a larger drug reservoir at the injection site, producing a more sustained absorption curve. Trough concentrations before the next monthly dose are comparable to those seen with 150 mg biweekly dosing, which is why the two regimens produce similar LDL-C reductions [1].

The clinical implication is direct: a dose administered 5 days late will still overlap with residual drug from the previous injection, producing continuous PCSK9 suppression. A dose administered 10 days late will not, and the patient will have experienced several days of un-suppressed PCSK9 activity and rising LDL-C before the late injection takes effect.

Alirocumab vs. Evolocumab: Missed-Dose Protocols Compared

Evolocumab (Repatha) is the other FDA-approved PCSK9 inhibitor, and patients sometimes switch between the two. The missed-dose rules differ slightly. For evolocumab 140 mg every 2 weeks, the prescribing information specifies a 7-day window identical to alirocumab [10]. For the 420 mg monthly dose, evolocumab's label also uses a 7-day cutoff.

The practical difference is that evolocumab's 420 mg monthly dose is administered via three consecutive 140 mg injections (using autoinjectors) or a single 420 mg infusion via the Pushtronex system. Missing one of the three injections within a single monthly session is a different problem than missing the entire session. Patients should administer all three injections within 30 minutes to count as a complete dose [10].

Both drugs have comparable half-lives and LDL-C rebound kinetics. A patient switching from one to the other can apply the same 7-day rule regardless of which PCSK9 inhibitor they are currently taking.

Special Populations: Adjustments for HeFH, Renal, and Hepatic Impairment

For patients with heterozygous familial hypercholesterolemia (HeFH), no dose adjustment is required for a missed dose beyond the standard 7-day protocol. HeFH patients often have higher baseline LDL-C and may experience a more pronounced absolute rebound in mg/dL terms, but the relative kinetics are the same [1].

Mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²) does not alter alirocumab pharmacokinetics in a clinically meaningful way, because the drug is cleared by catabolism rather than renal excretion [1]. No studies have been conducted in patients with severe renal impairment (eGFR <30), so caution is warranted, though the missed-dose rule itself does not change.

Mild hepatic impairment (Child-Pugh A) similarly requires no adjustment. Moderate to severe hepatic impairment has not been studied, and PCSK9 is produced in hepatocytes, so clinicians should monitor lipid response more closely in these patients [1]. If a patient with moderate hepatic impairment misses a dose and LDL-C rises above goal, the prescriber may consider checking a lipid panel 2 to 4 weeks after resuming treatment to confirm response.

Storage and Handling After a Missed Dose

A missed dose sometimes means the pen sat in the refrigerator longer than planned. This is fine. Alirocumab pens are stable under refrigeration (2 to 8 degrees Celsius) until the expiration date printed on the carton [1].

The concern arises if the pen was removed from the refrigerator and left at room temperature. Alirocumab may be kept at temperatures up to 25 degrees Celsius (77 degrees Fahrenheit) for a single period of up to 30 days. After 30 days at room temperature, the pen must be discarded, even if it has not been used [1]. If you removed a pen in anticipation of your scheduled injection, forgot to inject, and the pen has been at room temperature for fewer than 30 days, it is still usable for the late injection within the 7-day window.

Do not freeze alirocumab. Do not shake the pen. Do not use it if the solution appears cloudy, discolored, or contains visible particles [1].

The recommended injection sites are the thigh, abdomen (avoiding a 2-inch radius around the navel), or upper arm. Rotate sites with each injection to minimize injection-site reactions, which occur in approximately 7% of patients [1].